STOCK TITAN
  1. Home
  2. Sec-filings
  3. PRME
  4. [Form 4] Prime Medicine, Inc. Insider Trading Activity

Prime Medicine (PRME) director receives 75,000 options at $3.06

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Prime Medicine, Inc. director Jeffrey D. Marrazzo reported receiving a grant of stock options on June 5, 2026. The award covers 75,000 options to buy Prime Medicine common stock at an exercise price of $3.06 per share, held directly.

The options vest in full on the earlier of June 5, 2027 or the date of the next annual meeting of stockholders, provided he continues serving the company through that date. The options expire on June 5, 2036, and following this grant he holds 75,000 derivative securities of this type.

Positive

  • None.

Negative

  • None.
Insider Marrazzo Jeffrey D
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 75,000 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 75,000 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Stock options granted 75,000 options Stock option grant on June 5, 2026
Exercise price $3.06 per share Conversion or exercise price for granted options
Post-grant derivative holdings 75,000 derivative securities Total stock options following the transaction
Vesting date Earlier of June 5, 2027 or next annual meeting Full vesting condition subject to continuous service
Expiration date June 5, 2036 Option expiration for the 75,000 granted options
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
conversion or exercise price financial
"conversion_or_exercise_price: 3.0600"
expiration date financial
"expiration_date: 2036-06-05T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vest in full financial
"The shares subject to this option shall vest in full upon the earlier"
annual meeting of stockholders financial
"the date of the next annual meeting of stockholders"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Marrazzo Jeffrey D
(Last)(First)(Middle)
C/O PRIME MEDICINE, INC.
60 FIRST STREET
(Street)
CAMBRIDGE MASSACHUSETTS 02141
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Prime Medicine, Inc. [ PRME ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$3.0606/05/2026A75,000 (1)06/05/2036Common Stock75,000$075,000D
Explanation of Responses:
1. The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2027 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date.
Remarks:
/s/ Ryan Brown, attorney-in-fact06/08/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Prime Medicine (PRME) director Jeffrey D. Marrazzo report in this Form 4?

He reported receiving a grant of stock options from Prime Medicine, Inc.. The award covers 75,000 options to purchase common stock at a fixed exercise price, reflecting an additional equity-based position rather than an open-market share purchase.

How many Prime Medicine (PRME) options were granted to Jeffrey D. Marrazzo?

He was granted 75,000 stock options linked to Prime Medicine common stock. The Form 4 shows that after this award, he holds 75,000 derivative securities of this type, indicating the entire reported position comes from this single option grant.

What is the exercise price and expiration date of the PRME options granted?

The stock options carry an exercise price of $3.06 per share. According to the filing, these options are scheduled to expire on June 5, 2036, giving a long-term window during which they can be exercised once vested.

When do Jeffrey D. Marrazzo’s Prime Medicine options vest?

The options will vest in full on the earlier of June 5, 2027 or the date of Prime Medicine’s next annual stockholder meeting. Vesting is conditioned on his continuous service to the company through the applicable vesting date, as described in the footnote.

Is this Prime Medicine Form 4 a market purchase or an option award?

The Form 4 reflects an option award, not an open-market trade. It shows a grant of 75,000 stock options at a preset exercise price of $3.06, recorded under a transaction code for grants or awards rather than a purchase or sale.